At a glance
- Originator Merck & Co
- Class Antibacterials
- Mechanism of Action Deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 15 Jun 2001 No-Development-Reported for Gram-negative infections in USA (Parenteral)
- 12 May 1997 New profile
- 12 May 1997 Preclinical development for Gram-negative infections in USA (Parenteral)